FINACEA is unique. It is the first prescription gel approved by the FDA for treating the redness, bumps, and pimples associated with mild to moderate rosacea.
Here are a few of its key features:
- Water-based gel that is fragrance-free, and alcohol-free. It cools the skin, and is non-drying
- Safe and effective for treating the redness, bumps, and pimples of mild to moderate rosacea
- Contains AzA (azaleic acid), which is found naturally in the body and in foods such as whole grains, and has anti-inflammatory and antioxidant properties
- Works quickly. Some patients who used FINACEA saw their symptoms improve starting as early as 4 weeks
- Prolonged improvement. Some patients who used FINACEA experienced prolonged improvement in the redness, bumps, and pimples associated with mild to moderate rosacea
- Can be used in conjunction with nonirritating skin-care products and cosmetics
- Because of its proven effectiveness against the symptoms of rosacea, dermatologists consider FINACEA a first-line treatment option for rosacea sufferers
Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.
Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.
Images are for illustrative purposes only.